Istituto Europeo di Oncologia

Milan, MI 20142

0 studies enrolling now · 11 studies all time

What they study most

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Diffuse Large B-cell Lymphoma, Epithelial Ovarian Cancer, Exocrine Pancreatic Cancer, Fallopian Tube Cancer, Follicular Lymphoma, HER2-Positive Primary Breast Cancer, Lymphoma, Follicular, Lymphoma, T-Cell, Peripheral

Studies at this site

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL — Running, not enrolling
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Running, not enrolling
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors — Stopped early
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer — Completed
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) — Stopped early
Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) — Completed
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma — Completed
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma — Completed
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed